Response Evaluation Criteria In Solid Tumors (RECIST) was updated to version 1.1 in 2009.
For both RECIST 1.0 and 1.1, the requirement for measurable disease at baseline depends on the endpoints of the clinical trial.
The fundamental concept common to both versions of RECIST is that measurable...